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ABSTRACT
Objectives.Marijuanaisthemostcommonlyusedillicitdrugduringpregnancy.Due
to high lipophilicity, cannabinoids can easily penetrate physiological barriers like
the human placenta and jeopardize the developing fetus. We evaluated the impact
of cannabidiol (CBD), a major non-psychoactive cannabinoid, on P-glycoprotein
(P-gp) and Breast Cancer Resistance Protein (BCRP) expression, and P-gp function
in a placental model, BeWo and Jar choriocarcinoma cell lines (using P-gp induced
MCF7cells(MCF7/P-gp)forcomparison).
Study design. Following the establishment of the basal expression of these trans-
porters in the membrane fraction of all three cell lines, P-gp and BCRP protein
and mRNA levels were determined following chronic (24–72 h) exposure to CBD,
by Western Blot and qPCR. CBD impact on P-gp eZux function was examined
by uptake of speciﬁc P-gp ﬂuorescent substrates (calcein-AM, DiOC2(3) and rho-
damine123(rh123)).CyclosporineA(CsA)servedasapositivecontrol.
Results. Chronic exposure to CBD resulted in signiﬁcant changes in the protein and
mRNA levels of both transporters. While P-gp was down-regulated, BCRP levels
wereup-regulatedinthechoriocarcinomacelllines.CBDhadaremarkablydiVerent
inﬂuence on P-gp and BCRP expression in MCF7/P-gp cells, demonstrating that
these are cell type speciﬁc eVects. P-gp dependent eZux (of calcein, DiOC2(3) and
rh123)wasinhibiteduponshort-termexposuretoCBD.
Conclusions. Our study shows that CBD might alter P-gp and BCRP expression in
the human placenta, and inhibit P-gp eZux function. We conclude that marijuana
use during pregnancy may reduce placental protective functions and change its
morphologicalandphysiologicalcharacteristics.
Subjects Gynecology and Obstetrics, Pharmacology
Keywords Cannabidiol, Marijuana, Breast Cancer Resistance Protein (BCRP), P-glycoprotein
(P-gp), BeWo and Jar cells, Human placenta
INTRODUCTION
Until recently it was assumed that prenatal exposure to marijuana is frequently combined
with other drugs (e.g., tobacco and alcohol), making cannabis eVects diYcult to isolate
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DOI10.7717/peerj.153and assess (Kozer & Koren, 2001; Moore et al., 2010). However, the studies of Dekker et
al. and Hayatbakhsh et al. suggested that cannabis use prior to, during the ﬁrst trimester,
or throughout gestation is associated with a higher risk for a low birth weight and
neonatal length, as well as preterm labor (Dekker et al., 2012; Hayatbakhsh et al., 2012).
Moreover, the presence of the endocannabinoid receptors CB1 and CB2 on placental
syncytiotrophoblast(Habayebetal.,2008a),alongwithmarijuanabeingthemostpopular
drug of abuse among pregnant population (Brown & Graves, 2013), raised the need to
understandtheeVectofcannabinoidsontheplacenta.
Cannabidiol (CBD) is one of the most abundant cannabinoids in the marijuana plant
(Mechoulam&Shvo,1963;Mechoulam&Hanuˇ s,2002;Schieretal.,2012).Itisapromising
candidate for clinical utilization, due to low aYnity binding to CB1 and CB2 cannabinoid
receptorsandnocognitiveandpsychoactiveactivity(Zuardi,2008;Deiana,2012).
Preliminary data from in vitro models indicate that cannabinoids may interact
with human P-gp (ABCB1) and BCRP (ABCG2). Acute and long-term exposures to
cannabinoids were shown to alter P-gp expression and function (Holland et al., 2006;
Zhu et al., 2006). However, BCRP exposure to cannabinoids demonstrated functional
inhibitiononly(Hollandetal.,2007).
P-gp and BCRP are both thought to be protective for the fetus. These ATP-binding
cassette (ABC) eZux transporters expressed at the apical membrane of the polarized
syncytiotrophoblast layer (Ni & Mao, 2011), and play a signiﬁcant role in drug transfer
across the placental barrier (Lankas et al., 1998; Mao, 2008; Vahakangas & Myllynen,
2009; Myllynen, Kummu & Sieppi, 2010; Eshkoli et al., 2011). P-gp was found to be an
anti-apoptotic cellular agent (Smyth et al., 1998; Huls, Russel & Masereeuw, 2009) and
BCRP was shown to have a role in placental tissue and syncytial survival by protecting
cells from pro-apoptotic injuries (Evseenko et al., 2007; Evseenko, Paxton & Keelan, 2007;
Hardwick,Velamakanni&vanVeen,2007;Vahakangas&Myllynen,2009).
We have already assessed the interaction of CBD with placental BCRP, ﬁnding that in
both,in vitroandex vivosystems,CBDinhibiteditseZuxfunction(Feinshteinetal.,2013).
These results together with other recent ﬁndings regarding the eVect of cannabinoid on
theABCtransporterledustoinvestigatewhetherCBDaVectsplacentalP-gponfunctional
and placental P-gp and BCRP on expressional levels (Holland et al., 2006; Zhu et al., 2006;
Hollandetal.,2007;Holland,Allen&Arnold,2008).
In the present work the implications of CBD exposure on P-gp and BCRP expression
andP-gpfunctionistestedinahumantrophoblast-likecelllinesBeWoandJar,asplacental
model.
MATERIALS AND METHODS
Materials
BeWo and Jar cells were obtained from Dr. B. Ugele, Ludwig-Maximilians University,
Munich, Germany (Feinshtein et al., 2010; Polachek et al., 2010; Feinshtein et al., 2013).
MCF7/P-gp cells (BCRP expressing and P-gp induced cells), were kindly provided by
Prof. Esther Priel (Ben Gurion University, Beer Sheva, Israel) (Feinshtein et al., 2013). All
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 2/19materials for cell culture were purchased from Biological Industries (Israel). CBD was a
kindgiftfromProf.RaphaelMechoulam(TheHebrewUniversityofJerusalem,Jerusalem,
Israel).Calcein-AM, DiOC2(3), rh123 and cyclosporine A (CsA) were purchased from
Sigma-Aldrich(St.Louis,MO,USA).Alistofallantibodiesusedinthecurrentresearchis
summarizedinTableS1.
METHODS
Cell culture and drug treatments
MCF7/P-gp cells were cultured in conditions as previously described (Golan, Schreiber &
Avissar,2009),BeWoandJarcellswereculturedaspreviouslydescribed(Golan,Schreiber&
Avissar, 2009; Feinshtein et al., 2010). Brieﬂy, 24 h after seeding in 3510 mm cell culture
dishes (Corning), growth medium (DMEM for MCF7/P-gp, DMEM/F-12 for BeWo and
Jarcells,supplementedwith10%fetalbovineserum,2mML-glutamine,100g/mlstrep-
tomycin and 100 units/ml penicillin in a humidiﬁed atmosphere of 95% air and 5% CO2
at37C)wasreplacedwithfreshmediumcontainingCBD10or15M(initiallydissolved
in DMSO) or DMSO (0.08% or 0.12%, respectively, vehicle control). In order to achieve
long-termexposure,thetreatmentmediumwasrefreshedeverydayfor24h,48hor72h.
Subcellular fractionation
Fractionation procedure was carried out as previously described (Golan, Schreiber & Avis-
sar,2009),fortheisolationofthemembranefraction.Themembranefractionwasdiluted
in sample buVer 1:3 (10% v/v glycerol, 20% v/v SDS 20%, 5% v/v -mercaptoethanol,
0.05%w/vbromophenolblue,pH6.8),boiledfor5minat95C(forBCRPdetermination)
or incubated for 30 min at 37C (for P-gp determination) and frozen at  80C until
assayed. Aliquots were taken for protein determination using the Lowry assay. Fractions
puritywasveriﬁedusingspeciﬁcmarkers:NaC=KC ATPaseformembranesandNF/kBp65
forcytosol.
IMMUNOCYTOCHEMISTRY AND CONFOCAL
MICROSCOPY
MCF7/P-gp, BeWo and Jar cells were seeded on cover slips and grown to 70% sub-
conﬂuency. Cells were then ﬁxed in PFA for 15 min and stained with mouse anti-human
CD 243 (MDR-1) antibodies, diluted in PBS, containing 3% BSA, for 1 h at room
temperature, followed by incubation with Alexa Fluor 488 goat anti-mouse antibody in
PBS containing 3% BSA, for 1/2 h at room temperature. Cover-slips were washed 3 times
and mounted onto glass slides with DAPI (40,6-diamidino-2-phenylindole)-containing
ﬂuorescent mounting medium (DAPIFluoromount-G; SouthernBiotech). Immunoﬂuo-
rescencewasdetectedbyanOlympusFV-1000Spectralconfocallaserscanningmicroscope
with excitation at 488 nm and emission at 520 nm. Image analysis was performed using
ImageJv.1.40Csoftware.
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Cells were grown to conﬂuency in 6-well culture dishes, trypsinized, counted, and
0:5  106 cells were placed in light resistant vials. Cells were washed three times with
cold PBS (and each time centrifuged at 1200 g for 5 min), and incubated for 30 min with
BSA 3% in PBS. Following additional PBS wash, 50 L of BSA 1% in PBS and antibodies
wereadded(1:10anti-BCRPFITCconjugatedantibodyor1:10CBL602FFTICconjugated
isotype negative control). Cells were incubated in the dark at 4C for 1 h, washed with ice
coldPBS,re-suspended(in0.5mlPBS)andanalyzedbyFACS(BDFACSVantage).
Immunoblotting
Membrane fractions were thawed on the day of assay. Protein aliquots (60–100 g/lane)
were taken for protein separation by SDS-PAGE as previously described (Golan, Schreiber
& Avissar, 2009). Semi-quantitative analysis was carried out using a computerized image
analysis system (EZQuant-Gel 2.11; EZQuant Biology Software Solutions Ltd., Israel).
EqualproteinloadingwasensuredbynormalizationtoNaC=KC ATPase(forP-gp)oractin
(forBCRP).
RNA extraction, reverse transcription, real-time polymerase chain
reaction (qPCR)
Isolation and puriﬁcation of total RNA from BeWo and Jar cells was carried out using
EZ-RNA Kit (Biological Industries, Israel) according to manufacturer’s instructions. 1 g
oftotalRNAwasusedforreversetranscriptionusingHighCapacitycDNARTkit(Applied
Biosystems, Foster City, CA), in 20 l reaction volume. BCRP and P-gp mRNA was
measured by qRT-PCR, as indicated in the manufacturer protocol (Applied Biosystems,
Foster City, CA), and performed by the Applied Biosystems Real Time PCR system (7500
system), using TaqMan probes and primers for human BCRP, P-gp and actin (Applied
Biosystems, Foster City, CA). The cycling conditions for all primers were as follows: hold
for10minat95C,followedby40cyclesconsistingoftwosteps,15sat95C(denaturing),
and 1 min at 60C (annealing-extension). The threshold cycle, which correlates inversely
with the mRNA levels of target, was measured as the cycle number at which the reporter
ﬂuorescent emission increases above a threshold level. P-gp and BCRP mRNA levels were
normalized to actin mRNA in the same samples. Results were analyzed by the 2 1 1CT
method,demonstratingtherelativechangesingeneexpressionfromreal-timequantitative
PCRexperiments,using7500Softwarev2.0.4(AppliedBiosystems,FosterCity,CA).
P-gp substrate uptake experiments
Cells were pre-incubated for 30 min with CBD 10 or 25 M (working concentration
previously published (Holland et al., 2006; Ligresti et al., 2006; Zhu et al., 2006; Holland et
al., 2007; Holland, Allen & Arnold, 2008; De Filippis et al., 2011; Arnold et al., 2012; Harvey
et al., 2012; Hill et al., 2012; Maor et al., 2012; Solinas et al., 2012; Dud´ aˇ sov´ a et al., 2013;
Juknat et al., 2013; Nabissi et al., 2013), and initially dissolved in DMSO) or CsA 20 M
(known P-gp inhibitor used as positive control (Mori et al., 2012)), dissolved in transport
buVer (TB) (pH D 7.4) (Feinshtein et al., 2010), while “control cells” were pre-incubated
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 4/19in TB with the correlating concentration of DMSO. Following pre-incubation, P-gp
substrates were added (Calcein-AM or DiOC2(3) or rh123) (Minderman et al., 1996;
Martin et al., 2003) and cells were further incubated for 30 min. At the end of incubation
plates were treated as previously detailed (Feinshtein et al., 2010), and samples were
stored (at  20C) for further analysis. Intracellular ﬂuorescence of all P-gp substrates
was quantiﬁed by Inﬁnite M200 microplate reader (Tecan) and normalized to protein
amount (determined by Lowry method) (Lowry et al., 1951), or detected by an Olympus
FV-1000 Spectral confocal laserscanning microscope and analyzed using ImageJ v. 1.40C
software.
Statistical analysis
AllstatisticsandgraphswerecarriedoutusingGraphPadPrism5software.Student’st-test
orone-wayANOVAfollowedbyappropriateBonferronicorrectionswereused.
RESULTS
CBD impact on BCRP and P-gp protein expression
The changes in P-gp and BCRP protein levels in the membrane fraction of BeWo, Jar
and MCF7/Pgp cells were studied. Following determination of proper cell fractionation
(Fig. 1A), the basal expression of these two transporters in non-treated cells was
determined by Western Blot analysis (Fig. 1B). Due to unexpected P-gp expression proﬁle
in all three cell lines we veriﬁed its basal expression by immunocytochemical ﬂuorescent
staining(Fig.1C).ItcanbeseenthatourBeWo,JarandMCF7/P-gpcellsexpressdetectable
levels of P-gp. For P-gp expression, the results of the Western Blot were conﬁrmed by
immunocytochemistry showing that P-gp expression was the highest in MCF7/P-gp and
the lowest in Jar cells. For BCRP (ABCG2), results were conﬁrmed by FACS analysis,
showing that BCRP expression was much higher in JAR cells compared to BeWo cells (in
fullaccordancewithWesternBlotanalysis)(Fig.1D).
The changes in membrane BCRP and P-gp levels in BeWo cells following long-term
exposure to CBD are displayed in Fig. 2. Indeed, BCRP levels were signiﬁcantly increased
in a concentration-dependent manner (Fig. 2B) that was not time-dependent (Fig. 2A).
Following long-term exposure to CBD, P-gp protein levels signiﬁcantly decreased, in a
concentration-dependent manner (Fig. 2D), with no time-dependent eVect (Fig. 2C).
Similarly, in Jar cells (Fig. 3), BCRP protein concentrations was signiﬁcantly elevated
following long term exposure to CBD, in a concentration but not time-dependent eVect
(Figs. 3A and 3B). Due to very low P-gp initial (baseline) expression in the Jar cell line
(Figs. 1B and 1C), the expected down-regulation in P-gp expression following long-term
exposure to CBD is demonstrated in experiments of 72 h treatment only. P-gp is vaguely
visualized in the control group while it is almost undetectable in the CBD treated group
(Fig. 3C). 48 h exposure yielded the same results (P-gp levels were almost undetectable –
datanotshown),makingtimeandconcentrationdependentcomparisonsimpractical.
To examine whether CBD eVects are cell speciﬁc, the same experimental routine
was applied to MCF/P-gp cells. In these cells, BCRP and P-gp behavior under CBD
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 5/19Figure 1 Cell fractionation, P-gp and BCRP basal expression. (A) Cell fractionation: to verify proper
fractionation of whole cell lysate, membrane fractions and cytosolic fractions of BeWo, Jar, MCF/P-gp
cells were subjected to Western Blot analysis. NaC=KC ATPase served as membrane marker, and NF-B
(p65 subunit) served as cytosolic marker. (B) P-gp and BCRP basal expression in MCF7/P-gp, Jar and
BeWo cells was determined by Western Blotting. (C) Immunocytochemistry: ﬂuorescent staining of
BeWo, Jar and MCF7/P-gp cells with anti-P-gp antibody and DAPI. NC – negative control. (D) BCRP
(ABCG2) expression in choriocarcinoma cell lines BeWo and Jar as demonstrated by FACS analysis.
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 6/19Figure 2 Long-term exposure of BeWo cells to CBD: changes in P-gp and BCRP protein lev-
els. Long-term exposure of BeWo cells to CBD: changes in membrane BCRP and P-gp expressed levels.
Changes in BCRP-CBD concentration-dependent (B) and time-dependent (A). Changes in P-gp-CBD
concentration-dependent (D) and time-dependent (C). No statistical signiﬁcance between 48 and 72 h
time points. Data is displayed in means  s.d. of at least three .n D 9/ independent experiments of each
concentration or time point. One representative blot is presented for each experimental group. One-Way
ANOVA, followed by Bonferroni’s multiple comparison test, p < 0:01, p < 0:0001 compared to
control or comparison between groups as indicated.
inﬂuencewasprofoundlydiVerentfromthatseeninchoriocarcinomacelllines.P-gplevels
dramatically increased following long-term treatment with CBD, in a concentration- but
nottime-dependentmanner(Fig.4A).Atthesametime,BCRPexpressionwasnotaVected
byCBD(neithertime-,norconcentration-dependenteVectwasobserved)(Fig.4B).Thus,
we conclude that CBD has a cell-type speciﬁc inﬂuence upon long-term cellular exposure.
CBDimpactonMCF7/P-gpcellswasnotinvestigatedfurther.
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 7/19Figure 3 Long-term exposure of Jar cells to CBD: changes in P-gp and BCRP protein levels. Long-term exposure of Jar cells to CBD: changes in
membrane BCRP and P-gp expressed levels. Changes in BCRP-CBD concentration-dependent (B) and time-dependent (A). Changes in P-gp (C).
Data is displayed in means  s.d. of at least three .n D 12/ independent experiments of each concentration or time point. One representative blot is
presented for each experimental group. One-Way ANOVA, followed by Bonferroni’s multiple comparison test (Student’s t test for (C)), p < 0:05,
p < 0:0001 compared to control or comparison between groups as indicated.
CBD impact on BCRP and P-gp mRNA
To have a glimpse into the mechanism underlying the changes seen on the protein level
in BCRP and P-gp, we further focused to track the changes that occur on mRNA level of
these two transporters. In both, BeWo and Jar cells, BCRP mRNA quantiﬁcation showed
elevation following long-term exposure to CBD (Figs. 5A and 5C), and matched the
ﬁndingsonproteinlevel,supportingtranscriptionalup-regulation.Likewise,P-gpmRNA
expression signiﬁcantly dropped following long-term treatment with CBD, matching the
outcomes seen on the protein level (Figs. 5B and 5D), indicating that the changes in P-gp
levels following long-term CBD exposure results from transcriptional down-regulation
ratherthanpost-transcriptionalchanges.
CBD impact on P-gp function
Only BeWo and MCF7/P-gp cell lines were tested for P-gp inhibition by CBD due to the
fact that Jar cells expressed very low P-gp levels. In a preliminary study we observed a
non-cell type speciﬁc P-gp inhibition by 25 M CBD in both cell lines, as intracellular
calcein and rh123 ﬂuorescence was signiﬁcantly higher (elevation of 101  50% and
70  30%, respectively) in the presence of CBD (Figs. 6A and 6B). We further examined
whether lower concentration of CBD 10 M also inhibits P-gp, using two diVerent P-gp
speciﬁc substrates, calcein-AM and DiOC2(3). P-gp was inhibited following short-term
(1 h) exposure to CBD, as signiﬁcantly more DiOC2(3) and calcein (elevation of 20  8%
and249%,respectively)accumulatedinthecells(Figs.7Aand7B).
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 8/19Figure 4 Long-term exposure of MCF/P-gp cells to CBD: changes in P-gp and BCRP protein levels.
Long-term exposure of MCF/P-gp cells to CBD: changes in membrane P-gp (A) and BCRP (B) expressed
levels. Protein levels are given as percent of control levels. Data is displayed in means  s.d. of at least
three .n D 9/ independent experiments of each concentration or time point. One representative blot is
presentedforeachexperimentalgroup.One-WayANOVA,followedbyBonferroni’smultiplecomparison
test. p < 0:01, p < 0:0001 compared to control or comparison between groups as indicated.
DISCUSSION
Principal ﬁndings of the study
There is a dual eVect of CBD on the expression of BCRP and P-gp transporters in
trophoblast-like and in MCF7/P-gp cell lines. Under long-term CBD exposure BCRP
andP-gppresentcell-typespeciﬁcchangesinproteinandmRNAlevels.Occurringalready
atthetranscriptionallevel,P-gpproteinexpressionisdown-regulated,whilethatofBCRP
isup-regulated.Uponshort-termexposure,P-gpeZuxfunctionisinhibitedbyCBD.
Cannabinoid effects on pregnancy
Cannabis is extensively used in Western society as a recreational drug. The eVect of this
drug on pregnancy outcome was under constant debate; however, recently cannabis
consumption was reported to be associated with adverse pregnancy outcomes, including
preterm birth and fetal growth restriction (Dekker et al., 2012; Hayatbakhsh et al., 2012).
Although the mechanisms in which phytocannabinoids exert their eVects are not well
understood, there is accumulating evidence that endocannabinoids (like anandamide)
can inﬂuence reproduction, including fertilization, implantation, angiogenesis, embryo
development and placental growth (Taylor et al., 2007; Habayeb et al., 2008a; Lewis et al.,
2012; Solinas et al., 2012; Sun & Dey, 2012). One possible route to convey the eVect of
endocannabinoids is throughthe CB1 and CB2 receptorsthat are expressed by the human
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 9/19Figure 5 Long-term exposure of BeWo and Jar cells to CBD: changes in BCRP and P-gp mRNA
levels. (A), (C) changes in BCRP mRNA in BeWo and Jar cells (respectively). (B), (D) changes in P-gp
mRNA in BeWo and Jar cells (respectively). Values are given as fold of change compared to control.
Data is displayed as means  s.d. of at least three .n D 6/ independent experiments for each time
point. One-Way ANOVA, followed by Bonferroni’s multiple comparison test. p < 0:05, p < 0:01,
p < 0:0001 compared to control.
Figure 6 Non-cell type speciﬁc inhibition of P-gp by CBD 25 M. Non-cell type speciﬁc eVect of CBD
25 M on P-gp dependent calcein and rh123 intracellular eZux in (A) BeWo and (B) MCF7/P-gp cells.
Data presented from at least 2 independent experiments (n D 33;n D 11, respectively), as means  s.d.
Statistical signiﬁcance determined by Student’s t-test. p < 0:0001.
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 10/19Figure 7 Inhibition of P-gp by CBD 10 M in BeWo cells. CBD 10 M inhibition of P-gp dependent
eZux of calcein (A) and DiOC2(3) (B). Data presented from at least 2 independent experiments (n D 9,
n D 6, respectively), as means  s.d. Statistical signiﬁcance determined by One-Way ANOVA, followed
by Bonferroni’s multiple comparison test for (A) and student’s t-test for (B). p < 0:0001, p < 0:05.
trophoblast and provide a direct target for cannabinoids (Kenney et al., 1999; Habayeb et
al., 2008a; Habayeb et al., 2008b). However, not all endocannabinoids exert their eVect
through the classic cannabinoids receptors. For example, CBD lacks the central eVects of
cannabis and works through CB1 and CB2 independent model of action (Scuderi et al.,
2009). Since our goal was to test the direct cannabinoid eVect on trophoblast transporters
BCRP and P-gp, and CBD showed the most potent inhibitory eVect (among major
cannabinoids) on these transporters (Holland et al., 2006; Zhu et al., 2006; Holland et
al.,2007)itmadeCBDtheidealcannabinoidforthepresentstudy.
BCRP and P-gp signiﬁcance in pregnancy
BCRPandP-gpplayakeyroleinthetransportofdrugsandendogenouscompoundsinthe
humanplacenta,aVectingtheoutcomeofpregnancy(Robeyetal.,2009;Myllynen,Kummu
&Sieppi,2010).Theytransportabroadvarietyofstructurallydiversecompounds,someof
whicharecongruent(Frohlichetal.,2004;Mathias,Hitti&Unadkat,2005;Zhou,2008).In
addition,BCRPtransportsawiderangeofsubstrates,includingfetalhormonalprecursors
such as estrone-3-sulfate, naturally occurring carcinogens, porphyries and ceramides
(Imai et al., 2003; Krishnamurthy & Schuetz, 2005; Evseenko et al., 2007; Evseenko, Paxton
&Keelan,2007;Mao,2008;Dietrichetal.,2011).P-gpisexpressedintheapicalmembrane
of syncytiotrophoblast and probably is the main placental protective transporter during
the ﬁrst trimester. Its expression (both mRNA and protein) is the highest during the
ﬁrst trimester and decreases with advancing gestation (Gil et al., 2005; Mathias, Hitti &
Unadkat,2005;Sunetal.,2006).BCRPplaysanimportantroleasasurvivalfactorinBeWo
cellsaswellasinthehumanplacenta.Itisthoughttohaveaprotectiveantiapoptoticrolein
the trophoblast, regulating their survival under low oxygen conditions (Krishnamurthy &
Schuetz,2006;Yeboahetal.,2006;Evseenkoetal.,2007;Evseenko,Paxton&Keelan,2007).
Thetrophoblast expressionof BCRPmay changein diVerent pregnancy complications.
Indeed, placentas of women with preterm labor and intra-amniotic inﬂammation had
higher expressions of this transporter than those of women with preterm labor without
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IL-8, which also increased signiﬁcantly in placentas of women with preterm labor and
inﬂammation, suggesting that the transfer of drugs across the placenta may be altered in
casesofpretermlaborwithinﬂammation(Masonetal.,2011).
CBD impact on BCRP and P-gp upon long-term exposure
In the current study we have demonstrated for the ﬁrst time that the exposure of
trophoblast-like cell lines BeWo and Jar to CBD is associated with two distinct patterns
of eVects on the expression of the BCRP and P-gp transporters. The use of these cell lines,
instead of primary trophoblast cultures, results from the fact that primary trophoblasts
may rapidly diVerentiate in culture, continuously changing their gene and protein
expression(Evseenko,Paxton&Keelan,2006).Comparisonoftheseparameterswithregard
to CBD inﬂuences in such a dynamic in vitro environment would be almost impossible.
Moreover, BeWo and Jar cell lines, derived from human gestational choriocarcinoma,
commonly used as an in vitro model for trophoblast toxicology studies, and they oVer
a suitable model to study certain aspects of human trophoblast physiology, without the
aspectofinter-patientvariability(Sullivan,2004;Khareetal.,2006;Myrenetal.,2007).
The ﬁrst eVect that was observed following long-term exposure is that CBD tran-
scriptionally inhibited P-gp membrane expression (as mRNA levels of P-gp were also
dramatically reduced following long-term exposure to CBD). The long-term inhibitory
eVect of CBD on P-gp protein was previously reported in drug-selected human T
lymphoblastoid leukaemia cell line (CEM/VLB(100)) (Holland et al., 2006). The cell
speciﬁcity of CBD was previously reported (Khare et al., 2006; Hu, Ren & Shi, 2011),
yet our study is the ﬁrst to detect this phenomenon in trophoblast-like cell lines. This
observation may have clinical implications, in light of the role of P-gp as one of the key
transport mechanisms for numerous drugs in the human placenta, especially during the
venerable period of the ﬁrst trimester in which all the fetal organs are formed. Thus, our
resultsmightbeespeciallyimportanttowomenwhousecannabisonaregularbasisduring
theﬁrsttrimesterandaretreatedwithotherdrugsthatareP-gpsubstrates.
The expressional up-regulation of BCRP mRNA and protein in trophoblast-like
cell lines following long-term exposure to CBD is the second novel eVect reported
in our study. This observation is similar to that reported in trophoblasts of women
with preterm labor and inﬂammation, suggesting that (I) long-term exposure to CBD
may elicit an inﬂammatory response in trophoblast-like cell lines (Mason et al., 2011);
and (II) that this phenomenon could be a direct compensational consequence of
P-gp down-regulation, providing a working defense line to the developing embryo.
Interestingly, compensation of such nature was already described in murine placentas
(Hutson, Koren & Matthews, 2010). Nonetheless, the signal transduction of CBD action in
human placenta/trophoblast/choriocarcinoma cells has not been clearly reported yet and
needstobefurtherelucidated.
Feinshtein et al. (2013), PeerJ, DOI 10.7717/peerj.153 12/19CBD impact on P-gp upon acute exposure
In agreement with previously published data, we found that CBD holds inhibiting
properties over P-gp eZux function (Holland et al., 2006; Nieri et al., 2006; Zhu et al.,
2006). Moreover, our results show inhibition of P-gp eZux function in cell lines that
naturallyexpressthistransporter.ItcanbeseenthatCBD10M(Fig.7)yieldedinhibition
eVects lower than CBD 25 M (Fig. 6). Similar to results we recently presented (Feinshtein
et al., 2013), this observation could imply that CBD inhibits P-gp in a concentration
dependent fashion. However, due to diVerent quantiﬁcation methods used in the present
study,thisshouldbefurtherelucidated.
Of note, many of the drugs that are prescribed and considered safe to use during
pregnancy are in fact P-gp or BCRP substrates, like Loratadine and H2 blockers
(i.e., Ranitidine and Cimetidine) (Collett et al., 1999; Chen et al., 2003; Li et al., 2008;
Schwarz et al., 2008; Dahan & Amidon, 2009; Gill, O’Brien & Koren, 2009; Matok et al.,
2010). Our ﬁnding may have clinical implications, suggesting that the use of cannabis
duringgestationmayalterdrugtransportthroughthetrophoblastandleadtotheabsence
of a functional placental barrier during the ﬁrst trimester, leaving the developing embryo
unprotectedatthisvulnerableperiodofpregnancy.Moreover,thetrophoblastsofpregnant
women exposed to marijuana may exhibit some resistance to apoptotic and inﬂammatory
processesduetotheeVectofCBDonBCRPexpression.
CONCLUSIONS
Following cannabis consumption, all the drugs that are P-gp substrates can potentially
penetrate the human placental barrier at higher rates when combined with CBD, and
therefore their safety under these conditions is to be questioned. Additionally, changes in
placental BCRP expression proﬁle might lead to altered transplacental transport of BCRP
substrates,suchasmedications,naturallyoccurringcarcinogens,hormonalprecursorsand
apoptoticmolecules,andinﬂuencepregnancyoutcomes.
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